mEER Syngeneic Model Service for Squamous Cell Carcinoma

The mEER syngeneic model is an immunocompetent preclinical platform for HPV-positive squamous cell carcinoma of the head and neck, in which oropharyngeal epithelial cells carrying HPV16 E6, E7, and oncogenic H-Ras form tumors in syngeneic C57BL/6 hosts. Alfa Cytology provides the full mEER workflow—authenticated cell supply, flank or oral-cavity implantation, dosing, and immune endpoint analysis—so HPV-driven squamous cell carcinoma programs can progress from concept to decision-ready data.

Overview of mEER Syngeneic Model for Squamous Cell Carcinoma

The mEER line was generated by retroviral transduction of oropharyngeal epithelial cells from a male C57BL/6 mouse with HPV16 E6, HPV16 E7, and human H-Ras carrying the Gly12Val activating mutation (Hoover et al., 2007). Because high-risk HPV types drive a large and fast-growing share of human oropharyngeal squamous cell carcinoma, a murine tumor defined by the same viral oncoproteins offers a rare degree of etiologic fidelity: the E6 and E7 genes are not generic transforming cassettes here but the same shared tumor antigens that dominate human disease. The cells retain an epithelial identity, with cytokeratin and E-cadherin expression documented, and early work with the system already linked HPV16 E6 expression to anchorage-independent and invasive growth.

Fig 1. Generation and characterization of anti-PD-1 resistant mEER cells: iterative in vivo selection scheme, parental versus resistant tumor growth and survival in the C57BL/6 syngeneic model, Seahorse OCR/ECAR metabolic profiling, and pimonidazole/CD8/DAPI imaging showing increased hypoxia and reduced CD8+ T cells in resistant mEER tumors. (Zandberg, Dan P., et al., 2021)

Transplanted into syngeneic C57BL/6 mice, mEER cells establish tumors while the full immune repertoire of the host remains intact, which is precisely what the model is valued for. The viral antigens make it a natural testbed for therapeutic HPV vaccination, and the literature has used it to show that intranasal E6/E7 peptide vaccines paired with costimulatory or checkpoint agents, intratumoral TLR agonists combined with PD-1 blockade, and chemoradiotherapy supported by myeloid-directed immunomodulation can each reshape tumor immunity. Implantation is flexible—subcutaneous flank tumors of 1 × 10⁶ to 2 × 10⁶ cells for routine efficacy work, intradermal formats, or oral-cavity and tongue implantation monitored by MRI—and supporting tools include luciferase-tagged derivatives and anti-PD-1–resistant variants produced by iterative passage in tumor-bearing mice.

Cell Line Information: mEER

Beyond its transgenes, mEER carries neomycin- and puromycin-resistance cassettes from the retroviral constructs used in its engineering, and expression of HPV16 E6, HPV16 E7, and hRas transcripts is readily confirmable by RT-PCR—an authentication step that matters for a line distributed across many laboratories. Cultures are adherent and epithelial in appearance and are typically propagated in keratinocyte-type complete medium on coated vessels, consistent with their squamous epithelial origin. The system has also spawned practical derivatives: luciferase-tagged versions for whole-body imaging, an explant-derived line adapted to female hosts, and treatment-resistant variants, each extending what a single parental line can answer.

Our Services

With the mEER system, Alfa Cytology supports programs that need more than a tumor-growth curve: antigen-specific responses against the viral oncoproteins, checkpoint synergy, and treatment sequencing can all be examined in one immunocompetent setting. Studies can be staged from in vitro characterization through in vivo efficacy and combination work, with MRI-based oral-cavity monitoring and multiplex immune profiling available whenever the design calls for them.

Workflow of mEER Syngeneic Model Construction

Standing up an mEER study involves a defined chain of activities from cell verification to final analysis. The outline below shows the sequence most programs follow; routes, group sizes, and endpoints are adapted to each sponsor’s questions.

1. Cell sourcing and verification: Authenticated mEER stocks are revived, expression of HPV16 E6/E7 and hRas is confirmed (for example by RT-PCR), mycoplasma clearance is documented, and cultures are in vitro expanded to the planned scale.
2. Study blueprint: The implantation route (subcutaneous flank, intradermal, or oral-cavity/tongue), cohort structure, randomization, and humane endpoints are fixed in a written plan before animal work starts.
3. Inoculation: mEER suspensions are injected into C57BL/6 mice: commonly 1 × 10⁶ to 2 × 10⁶ cells for flank implants and about 2.5 × 10⁵ cells for intradermal formats; oral-cavity implants enter an MRI-based monitoring track.
4. Tumor take and baseline: Implanted tumors are tracked on a set schedule by caliper or imaging until they enter the enrollment window, frequently defined around 100–150 mm³.
5. Arm assignment and dosing: Mice are balanced into vehicle, benchmark, and test-article groups, after which antibodies, vaccines, radiation fractions, or small molecules are administered according to the protocol.
6. In-life monitoring: Tumor dimensions, body weight, and clinical status are recorded at defined intervals, with interim imaging added for luciferase-tagged cohorts.
7. Termination and analysis: At endpoint, tumors are excised and weighed; tumor-infiltrating lymphocytes are phenotyped by flow cytometry, sections undergo immunohistochemistry or multiplex immunofluorescence, and cytokine profiles are measured before statistics are compiled into the final report.

Fig 2. mEER Syngeneic Model construction workflow.

Case Study-mEER Syngeneic Model Development

Alfa Cytology has applied the mEER platform to preclinical questions that include mucosal HPV E6/E7 peptide vaccination combined with checkpoint modulation, intratumoral innate immune agonists paired with PD-1 blockade, chemoradiotherapy supported by myeloid-directed immunomodulation, and small-molecule strategies targeting DNA-damage response or tumor metabolism. Across these programs, readouts have covered tumor growth and survival, viral-antigen-specific T-cell responses, and the myeloid and lymphoid composition of the tumor microenvironment, with study-specific details available once confidentiality terms are in place.

Why Choose Alfa Cytology?

Choosing a partner for HPV-positive squamous cell carcinoma work means finding a team comfortable with both mucosal oncology and immunology-driven endpoints. Alfa Cytology brings those disciplines together inside a single preclinical workflow.

• Etiologic fidelity: tumors driven by HPV16 E6/E7 recapitulate in in vivo the viral antigen biology that defines human HPV-positive disease.
• Route versatility: flank, intradermal, and oral-cavity implantation formats suit efficacy, mechanistic, and imaging-heavy designs.
• Combination-ready protocols: vaccines, checkpoint antibodies, radiation fractions, and small molecules integrate within a single study plan.
• Depth of immune readouts: TIL phenotyping, multiplex immunofluorescence, and antigen-specific assays are performed in-house.
• Quality foundation: authenticated cells with confirmed transgene expression, IACUC-supervised SPF husbandry, and enforced humane endpoints.
• Sponsor visibility: scheduled updates, shared raw data, and reports formatted for internal review boards and publication.

Contact Us

Curious whether the mEER model fits your HPV-positive squamous cell carcinoma program? Reach out to our team for a scoping conversation and a tailored study outline. Alfa Cytology is ready to help you design the next experiment—contact us to get the conversation started.

For research use only. Not intended for any clinical use.